Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + zileuton
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy consists of aspirin, a nonsteroidal anti-inflammatory drug (NSAID), and zileuton, a 5-lipoxygenase inhibitor. Developed by the National Cancer Institute (NCI) for lung cancer prevention, the regimen aims to inhibit both the cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways of arachidonic acid metabolism. By reducing the production of pro-inflammatory prostaglandins and leukotrienes, the combination is hypothesized to modulate tobacco-related gene expression signatures and reduce the risk of lung carcinogenesis in current smokers. A Phase II trial (NCT02348203) evaluated this combination's effect on biomarkers in the nasal and bronchial epithelium, showing favorable modulation of a bronchial gene expression signature associated with squamous dysplasia.
- Other names
- aspirin and zileutonaspirin/zileuton
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on aspirin + zileuton.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + zileuton.